Effect of Xuezhikang Capsule on serum tumor necrosis factor-alpha and interleukin-6 in patients with nonalcoholic fatty liver disease and hyperlipidemia.
- Author:
Xiao-fen FAN
1
;
Yin-quan DENG
;
Lei YE
;
You-di LI
;
Jiu CHEN
;
Wen-wen LU
;
Jian-ping LI
Author Information
- Publication Type:Journal Article
- MeSH: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; administration & dosage; pharmacology; Capsules; Drugs, Chinese Herbal; administration & dosage; pharmacology; Fatty Liver; blood; complications; drug therapy; Female; Humans; Hyperlipidemias; blood; complications; drug therapy; Hypolipidemic Agents; administration & dosage; pharmacology; Interleukin-6; blood; Lipids; blood; Liver; drug effects; physiopathology; Liver Function Tests; Male; Middle Aged; Treatment Outcome; Tumor Necrosis Factor-alpha; blood
- From: Chinese journal of integrative medicine 2010;16(2):119-123
- CountryChina
- Language:English
-
Abstract:
OBJECTIVETo evaluate the effect of Xuezhikang Capsule on the serum levels of inflammatory factors such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in patients with nonalcoholic fatty liver disease (NAFLD) and hyperlipidemia, and to explore whether it has anti-inflammatory effect.
METHODSA total of 84 patients were randomly assigned to two groups with stratified block randomization, the treatment group (42 cases) and the control group (42 cases). They were treated with Xuezhikang Capsule and polyene phosphatidylcholine capsule for twenty-four weeks, respectively. The changes in serum TNF-alpha and IL-6 were measured by enzyme linked immunosorbent assay before treatment and at the 12th and 24th week.
RESULTSCompared with those before treatment, the serum levels of TNF-alpha and IL-6 significantly decreased in both groups after treatment (P<0.01). There was no significant change between the two groups for the treatments at different time points (P>0.05) and between the two groups for treatments at the same time points (P>0.05).
CONCLUSIONXuezhikang Capsule can inhibit the serum inflammatory factor in patients with NAFLD and hyperlipidemia.
